PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness
Abstract
Recently approved treatments and updates to genetic testing recommendations for prostate cancer have created a need for correlated analyses of patient outcomes data via germline genetic mutation status. Genetic registries address these gaps by identifying candidates for recently approved targeted treatments, expanding clinical trial data examining specific gene mutations, and understanding effects of targeted treatments in the real‐world setting.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 14, 2023
- Source ID
- 10.1002/pros.24650
Entities
People
- Alexandra O Sokolova
- Alicia K Morgans
- Andrew J. Armstrong
- Biren Saraiya
- Channing J Paller
- Christina Tran
- Christopher George
- Elisabeth I Heath
- Elyn Riedel
- Heather H Cheng
- Jacob Vinson
- Jo Ann B. Elrod
- Joelle Sigmond
- Justin Lorentz
- Leonard J. Appleman
- Maha H. A. Hussain
- Mark Fleming
- Matthew Orton
- Natalie Macario
- Pedro Coelho Barata
- Promise Trial Investigators
- Rana R. Mckay
- Rebecca Green
- Robert Dreicer
- Roberto Pili
- Shifeng Mao
- Tiffani A. Demarco
- Walter M. Stadler
Organizations
- Allegheny Health Network
- Cleveland Clinic
- Duke Cancer Institute
- Fred Hutchinson Cancer Center
- Indiana University
- Johns Hopkins University
- Northwestern University
- Rutgers University–New Brunswick
- Sunnybrook Health Sciences Centre
- UH Cleveland Medical Center
- United States Department of Defense
- University at Buffalo
- University of California, San Diego
- University of Chicago
- University of Pittsburgh
- University of Virginia
- University of Washington
- Virginia Oncology Associates
- Wayne State University